CB-03-01 is a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.

CB7921220 is an inhibitor of Adenylyl Cyclase isoform-1 (AC1) and isoform-6 (AC6).

CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM).

CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, GRK5 and GRK1, respectively.

CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity.

CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies.

CDC25 Phosphatase Inhibitor I, BN82002, is a cell-permeable ortho-hydroxybenzylamino compound that has been reported to display antitumor properties.

CDDO-2P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid.

CDDO-3P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid.

CDDO-imidazolide is a potent inducer of heme oxygenase-1 and Nrf2/ARE signaling,with potent antiproliferative, differentiating, and anti-inflammatory activities.

C-DIM12 is a novel synthetic activator of Nurr1.

CDK2 inhibitor 73 is a potent, selective CDK2 inhibitor with IC50 of 44 nM for CDK2/cyclin A, displays 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM)..

(S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized?E3 ligase ligand-linker conjugate?that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 hydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1.

BAM 7 is a direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

A specific and membrane-permeable inhibitor of the InsP3Kinase activity of ITPKA (inositol-1,4,5-trisphosphate-3-kinase A) with IC50 of 20 uM.

b-AP15(NSC687852) is a specific inhibitor of the deubiquitinating enzymes UCHL5 and Usp14 of the 26S proteasome. It blocks the deubiquitinating activity of the 26S proteasome.

BCI-215 (BCI215) is a potent, tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor.

BIBX 1382 is a potent, selective inhibitor of EGFR tyrosine kinase (IC50 = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 μM) and a range of other related tyrosine kinases (IC50 > 10 μM).

A prodrug of Brivanib, which is a dual inhibitor of VEGFR2 and FGFR1 with IC50 of 25 nM and 148 nM respectively.

A potent and highly selective CaMKII inhibitor with IC50 of 63 nM.

CAY10650 is a highly potent (IC50 = 12 nM) cPLA2α inhibitor.

A potent SHIP2 inhibitor that enhances in vitro insulin signaling through the Akt pathway more efficiently than AS1949490, and ameliorates abnormal glucose metabolism in diabetic (db/db) mice.

CDM-NAG is a useful tool compound to deliver the siRNA.

CEP-28122 is a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2.

CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).

Cephalotaxine is an antiviral as well as antitumor agent.

Get 73 has been investigated for the treatment of Alcohol Dependence.

GW 791343 hydrochloride is a P2X7 allosteric modulator.